Tikun Olam® Ltd., the first, largest and foremost government-licensed producer of medical cannabis in Israel, on Thursday announced a joint partnership in New York State with Compassionate Care Center of New YorkTM (CCCNY), a privately held New York-based biopharmaceutical company applying to be a Registered Organization under New York's Compassionate Care Act, and MedReleaf Corp., a privately held federally-licensed producer and distributor of medical-grade cannabis in Canada, which has set the gold standard for the industrial production of medical-grade cannabis in North America.
Founded in 2005, Tikun Olam is the only large-scale industrial producer of medical cannabis in Israel, supplying one third of qualifying Israeli patients with pharmaceutical-grade products. Tikun Olam has the most extensive patient experience treatment database in the field of medical cannabis with over 10,000 patients being monitored for nearly a decade and the data for the treatment of each patient's ailments recorded along with the efficacy of the different strain variations and dosages administered.
It is the only private company to have its proprietary medical strains of specifically-bred cannabis clinically tested on humans and referenced by name in peer-reviewed published articles reporting on the successful trials. In fact, Tikun Olam's strain Erez® was used in the only completed double-blind-placebo clinical trial on humans for Crohn's disease, which resulted in complete remission for 50 percent of the patients in the cannabis group and 10 percent in the controlled group.